Bone Biologics Reports Third-Quarter 2026 Net Loss of $618,000
Bone Biologics reported a net loss of $618,000 and diluted loss per share of $0.17 for the third quarter of 2026, compared with a $667,000 loss a year earlier.
Bone Biologics reported a net loss of $618K in the third quarter of 2026, compared with a $667K loss in the prior-year quarter, as it continued development work on its NELL-1 bone graft program.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Bone Biologics Corp [ BBLG ] - 10-Q - Oct. 26…